Hessell, A J; Poignard, P; Hunter, M; Hangartner, L; Tehrani, D M; Bleeker, W K; Parren, P W H I; Marx, P A; Burton, D R (2009). Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature Medicine, 15(8):951-954.
Hessell, A J; Rakasz, E G; Poignard, P; Hangartner, L; Landucci, G; Forthal, D N; Koff, W C; Watkins, D I; Burton, D R (2009). Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathogens, 5(5):e1000433.
Hessell, A J; Hangartner, L; Hunter, M; Havenith, C E G; Beurskens, F J; Bakker, J M; Lanigan, C M S; Landucci, G; Forthal, D N; Parren, P W H I; Marx, P A; Burton, D R (2007). Fc receptor but not complement binding is important in antibody protection against HIV. Nature, 449(7158):101-104.
Graus, Y F; de Baets, M H; Parren, P W; Berrih-Aknin, S; Wokke, J; van Breda Vriesman, P J; Burton, D R (1997). Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. Journal of Immunology, 158(4):1919-29.